The European Medicines Agency warned for the second time in 2016 that some of the top-selling hepatitis C treatments could reactivate hepatitis B in patients.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2016-12-02 10:49:332016-12-02 12:52:33EMA warns hep C drugs could reactivate hep B
